| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Factors associated with the treatment effect,including RAVs in the NS3 region, were examined in 21 patients with genotype 1b HCV infection who were treated with SMV-based therapy after failure of TVR-based therapy.
The SVR rate was 50% (10/20,PPS).Ultra-deep sequencing at the start of SMV-based therapy revealed that TVR-resistant variants were detected in 6 patients (29%),and no variants at position 168 were observed. Cross-resistant variants between TVR and SMV were detected in only one patient(SVR).Higher SVRs for SMV-based therapy were attained in relapsers to prior Peg-IFN plus RBV therapy (relapsers 100% vs non-responders 20%, p = 0.007).
In this study, ultra-deep sequencing analysis revealed that TVR and/or SMV-resistant variants may have no influence on the effect of SMV-based therapy after failure of TVR-based therapy. Relapsers to previous Peg-IFN/RBV therapy would be a good candidate for retreatment with SMV-based triple therapy.
|
